CHS-114 + toripalimab + 5-fluorouracil + cisplatin

CHS-114 + toripalimab + 5-fluorouracil + cisplatin is an experimental combination therapy for advanced solid tumors, including head and neck and gastric cancers. - **CHS-114** is a human, afucosylated anti-CCR8 monoclonal antibody designed to deplete CCR8-positive regulatory T cells in the tumor microenvironment, enhancing immune-mediated tumor destruction through antibody-dependent cellular cytotoxicity (ADCC) and/or phagocytosis (ADCP)[1][3]. - **Toripalimab** is a monoclonal antibody checkpoint inhibitor targeting PD-1, designed to enhance anti-tumor immune activity by blocking the PD-1 pathway, thereby promoting T-cell mediated immunity[1][3]. - **5-fluorouracil** is a small molecule antimetabolite inhibiting thymidylate synthase, preventing DNA synthesis and promoting apoptosis in rapidly dividing cells such as tumor cells[2][6][8][10]. - **Cisplatin** is a platinum-based small molecule chemotherapy that causes DNA crosslinking and cell death in proliferating tumor cells[2][6][8][10]. This combination is currently under clinical investigation to evaluate safety and efficacy, with preliminary results indicating immune microenvironment modulation, anti-tumor activity, and a side effect profile consistent with the components[1][9].

Other names

5-fluorouracilcisplatin5FU